Di-substituted pyrazole compounds for the treatment of diseases

A Compound of Formula (I):

• where
• R1 is pyridinonyl, where the pyridinonyl is substituted on its nitrogen with R1b and is additionally optionally substituted with 1 R1a;
• R1a, when present, is halo, alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, or heterocycloalkylalkyl;
• R1b is hydrogen, alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, or heterocycloalkylalkyl;
• R2 is
• where 0, 1, or 2 of X1-X4 are nitrogen and the remaining are CH or CR2b;
• R2a is −OR5, —S(O)R6, or —S(O)2R7;
• each R2b, when present, is independently halo, alkyl, haloalkyl, —NO2, or cyano;
• R3 is hydrogen, halo, alkyl, or haloalkyl;
• R4 is hydrogen, halo, alkyl, or haloalkyl;
• and
• R5, R6, and R7 are independently alkyl;
• haloalkyl;
• hydroxyalkyl;
• haloalkyl further substituted with 1 or 2 hydroxy;
• cycloalkyl;
• cycloalkylalkyl;
• heterocycloalkyl;
• or heterocycloalkylalkyl;
• where the cycloalkyl, alone or as part of cycloalkylalkyl, and heterocycloalkyl, alone or as part of heterocycloalkylalkyl, are optionally substituted with 1, 2, or 3 groups independently selected from alkyl, hydroxy, halo, and hydroxyalkyl;
• or
• a stereoisomer, a mixture of stereoisomers, and/or a pharmaceutically acceptable salt thereof.